$NERV Cashflow Statement | Understand Stock

$NERV

$2.23 +$0.03 (1.36%) Close

$NERV Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net (loss) income
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Impairment of in-process research and development
Depreciation and amortization
Amortization of capitalized software
Amortization of right-of-use assets
Stock-based compensation expense
Loss on issuance of convertible preferred stock and warrants
Warrant issuance cost
Changes in fair value of the warrant liability
Non-cash interest expense associated with the sale of future royalties
Deferred taxes
Remeasurement of liability related to sale of future royalties

Changes in operating assets and liabilities
Refundable regulatory fee
Prepaid expenses and other current assets
Capitalized software
Other noncurrent assets
Accounts payable
Accrued expenses and other current liabilities
Operating lease liabilities, current

Net cash used in operating activities
Cash flows from investing activities:
Purchases of equipment
Net cash provided by investing activities

Cash flows from financing activities:
Proceeds from the sale of future royalties
Proceeds from sales of common stock and warrants in private placement
Costs paid in connection with private placement
Payment of deferred offering costs
Fees paid in connection with the reverse stock split fractional shares
Net cash provided by (used in) financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents, and restricted cash
Beginning of period
End of period
Reconciliation of the Condensed Consolidated Statements of Cash Flows to the Condensed Consolidated Balance Sheets
Cash and cash equivalents
Restricted cash
Total cash, cash equivalents, and restricted cash
Supplemental disclosure of non-cash financing activities
Initial recognition of warrant liability at fair value
Deferred issuance costs included in accounts payable and accrued expenses

Comments